Agents contributing to secondary immunodeficiency development in patients with multiple myeloma, chronic lymphocytic leukemia and non-Hodgkin lymphoma : a systematic literature review

Autor: Jolles, Stephen, Giralt, Sergio, Kerre, Tessa, Lazarus, Hillard M., Mustafa, S. Shahzad, Ria, Roberto, Vinh, Donald C.

Publikováno v: FRONTIERS IN ONCOLOGY

IntroductionPatients with hematological malignancies (HMs), like chronic lymphocytic leukemia (CLL), multiple myeloma (MM), and non-Hodgkin lymphoma (NHL), have a high risk of secondary immunodeficiency (SID), SID-related infections, and mortality. H

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d05167422302d9b63b5f69f1f31ad687
https://biblio.ugent.be/publication/01H32B6E3ZJ04HTWH2DYT14XT1

EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for haematological malignancies

Autor: Kiesewetter, B., Cherny, N. I., Boissel, Nicolas, Cerisoli, F., Dafni, U., De Vries, Elisabeth G. E., Ghia, Paolo, Gökbuget, N., González-Calle, Verónica, Huntly, B., Jäger, U., Latino, N. J., Douillard, Jean-Yves, Malcovati, L., Mateos, M. V., Ossenkoppele, G. J., Porkka, K., Raderer, M., Ribera, Jose-Maria, Scarfò, L., Wester, R., Zygoura, P., Sonneveld, P., Universitat Autònoma de Barcelona

Publikováno v: ESMO Open, 5. BMJ Publishing Group
Kiesewetter, B, Cherny, N I, Boissel, N, Cerisoli, F, Dafni, U, de Vries, E G E, Ghia, P, Gökbuget, N, González-Calle, V, Huntly, B, Jäger, U, Latino, N J, Douillard, J-Y, Malcovati, L, Mateos, M-V, Ossenkoppele, G J, Porkka, K, Raderer, M, Ribera, J-M, Scarfò, L, Wester, R, Zygoura, P & Sonneveld, P 2020, ' EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for haematological malignancies ', ESMO OPEN, vol. 5, no. 1, e000611 . https://doi.org/10.1136/esmoopen-2019-000611
ESMO OPEN, 5(1):e000611. BMJ Publishing Group
ESMO Open, 5(1):000611. BMJ PUBLISHING GROUP
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
ESMO Open

OBJECTIVE: Value frameworks in oncology have not been validated for the assessment of treatments in haematological malignancies, but to avoid overlaps and duplications it appears reasonable to build up experience on existing value frameworks, such as

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::afab66d40083bafe1f8491e208c2d914
https://pure.eur.nl/en/publications/bb5892b7-da0a-4ca4-abcf-2b2429eeebe8

Response of oral Melphalan, Prednisone and Thalidomide (MPT) on symptomatic multiple myeloma patients who are non-transplant candidates

Autor: Muhammad Kamruzzaman, Mohiuddin Ahmed Khan, Jannatul Ferdous, Sirajul Islam

Publikováno v: Journal of Dhaka Medical College. 25:61-66

Background: Oral melphalan, prednisone and Thalidomide (MPT) has been tested and proved efficacy in multiple myeloma (MM). But, no data are available on the response rate and adverse effect of oral MPT in diagnosed symptomatic MM patients who are non

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6d184cae5c20dd69e59ec2705fdd0a15
https://doi.org/10.3329/jdmc.v25i1.33957

Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial

Autor: Sebastian Grosicki, Ming Qi, Ying Chen, Andre Crepaldi, Jon Ukropec, Sung-Soo Yoon, Zsolt Nagy, Genadi Iosava, Jianping Wang, Maria-Victoria Mateos, Tomoaki Fujisaki, Anupa Kudva, Chantal Doyen, Joan Bladé, Mark Cook, Stefan Knop, Anna Marina Liberati, Philip Campbell, Michele Cavo, Tatiana Shelekhova, Andrzej Jakubowiak, Susan Wroblewski, Jesús F. San-Miguel, Paulo Sérgio Lucio, Rachel Kobos, Ludek Pour, Kenshi Suzuki, Maria Krevvata, Meletios A. Dimopoulos, Mamta Garg

Publikováno v: Lancet, Vol. 395, no. 10218, p. 132-141 (2020)

Background: Standard-of-care treatment for patients with newly diagnosed multiple myeloma includes combination therapies for patients who are not eligible for autologous stem-cell transplantation. At the primary analysis for progression-free survival

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ddaceab5bcc5396f9b58fc6f1f9d2321
https://pubmed.ncbi.nlm.nih.gov/31862988

Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN)

Autor: Alessandra Larocca, Sandra Maria Dold, Sonja Zweegman, Evangelos Terpos, Ralph Wäsch, Mattia D’Agostino, Sophia Scheubeck, Hartmut Goldschmidt, Francesca Gay, Michele Cavo, Heinz Ludwig, Christian Straka, Sara Bringhen, Holger W. Auner, Jo Caers, Martin Gramatzki, Massimo Offidani, Meletios A. Dimopoulos, Hermann Einsele, Mario Boccadoro, Pieter Sonneveld, Monika Engelhardt

Publikováno v: Larocca, A, Dold, S M, Zweegman, S, Terpos, E, Wäsch, R, D’Agostino, M, Scheubeck, S, Goldschmidt, H, Gay, F, Cavo, M, Ludwig, H, Straka, C, Bringhen, S, Auner, H W, Caers, J, Gramatzki, M, Offidani, M, Dimopoulos, M A, Einsele, H, Boccadoro, M, Sonneveld, P & Engelhardt, M 2018, ' Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN) ', Leukemia, vol. 32, no. 8, pp. 1697-1712 . https://doi.org/10.1038/s41375-018-0142-9
Leukemia, 32(8), 1697-1712. Nature Publishing Group

Multiple myeloma is a disease typical of the elderly, and, because of the increase in life expectancy of the general population, its incidence is expected to grow in the future. Elderly patients represent a particular challenge due to their marked he

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::37d8a70689fbfafffe6b448c208e672d
http://hdl.handle.net/10044/1/58981